Foghorn Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.345; its P/E ratio is -2.46; Foghorn Therapeutics is scheduled to report earnings on May 6, 2024, and the estimated EPS forecast is $-0.63. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 17.48M	$ 5.60M	$ 5.31M	$ 4.18M	$ 6.63M
Gross Profit	$ 17.48M	$ 5.60M	$ 5.31M	$ 4.18M	-
EBIT	$ -13.61M	$ -28.55M	$ -33.32M	$ -29.31M	$ -25.77M
EBITDA	$ -13.36M	$ -28.48M	$ -33.19M	$ -29.08M	$ -24.93M
Net Income Common Stockholders	$ -14.31M	$ -29.49M	$ -30.53M	$ -28.89M	$ -25.77M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 259.89M	$ 284.31M	$ 315.97M	$ 345.80M	$ 373.50M
Total Assets	$ 313.42M	$ 339.58M	$ 372.88M	$ 404.88M	$ 433.93M
Total Debt	$ 47.08M	$ 47.94M	$ 49.84M	$ 51.51M	$ 53.17M
Net Debt	$ -212.81M	$ -236.37M	$ -266.13M	$ -294.29M	$ -320.33M
Total Liabilities	$ 370.81M	$ 388.93M	$ 397.47M	$ 404.77M	$ 409.61M
Stockholders Equity	$ -57.39M	$ -49.34M	$ -24.56M	$ 112.00K	$ 24.32M
Cash Flow	-
Free Cash Flow	$ -27.23M	$ -32.73M	$ -31.79M	$ -29.19M	$ -20.32M
Operating Cash Flow	$ -27.15M	$ -32.26M	$ -31.15M	$ -28.92M	$ -19.99M
Investing Cash Flow	$ 38.43M	$ 39.13M	$ 29.50M	$ -6.51M	$ 46.05M
Financing Cash Flow	$ 1.39M	$ 103.00K	$ 102.00K	$ 16.00K	$ 333.00K

Currency in USD

Foghorn Therapeutics Earnings and Revenue History

Income Statement >

Foghorn Therapeutics Debt to Assets

Balance Sheet >

Foghorn Therapeutics Cash Flow

Cash Flow >

Foghorn Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing